IMMUNWORK

Immunwork is developing a number of new drug candidates based on our T-E pharmaceutical and multi-arm linker platforms... After a corporate reorganization in November 2019, Immunwork is now a wholly owned subsidiary of T-E Pharma Holding, incorporated in Cayman Island. Immunwork focuses on the research and development of a class of new drugs, which are created based on our proprietary "T-E TM pharmaceuticals" technology platform. The first group of new drugs is for treating several types of cancer, diabetes, obesity, fatty liver diseases, and pathological blood clots.

Also known as: Immunwork, Inc., MIRACLE

Primary location: Taipei Taiwan R.o.c.